An 84-year-old woman presented to her hematologist’s office with an
asymptomatic leukocytosis and associated lymphocytosis seen on routine blood
work. She noted complaints of fatigue and had an unintentional weight loss of
15 lb within 1 year. At the time of initial consultation, her blood work showed
a total white blood cell count of 25,000 cells/mcL with 75% lymphocytes, which
fluctuated to as high as 33,000 cells/mcL with 76% lymphocytes. She also had a
normocytic anemia and normal renal function, but workup revealed an elevated
serum globulin level, elevated lactate dehydrogenase, and a beta-2
microglobulin of 7,303. Peripheral smear exam was consistent only with small
Serum protein electrophoresis showed a polyclonal gammopathy. Flow
cytometry analysis of peripheral blood showed a population of cells that
expressed a monoclonal lambda pattern, which were CD5+, CD23–, CD20+ and
cyclin D1+. Lambda was brightly expressed. To note, CD10, CD11C and CD56 were
all negative. Peripheral blood fluorescence in situ hybridization (FISH)
analysis was positive for an 11:14 (CCND1/IGH) translocation in 81.5% of the
cell population, which is typical of mantle cell lymphoma. The probes were
negative for bcl-2 and bcl-6.
(Clockwise from top left – CT image, PET image, whole body
maximum intensity projection PET image, CT/PET fusion image). There is
hypermetabolic lymphadenopathy in the right level I cervical station
Photo courtesy of Munir Ghesani, MD
hypermetabolic left axillary lymphadenopathy (arrow).
PET/CT performed in June 2010 showed evidence of lymphadenopathy in the
neck, chest, abdomen and pelvis, with associated increased SUV activity;
diffuse hypermetabolic enlarged spleen; heterogeneous uptake throughout the
axial and appendicular skeleton; bilateral palatine tonsils associated with
hypermetabolic activity; and a stable left adrenal nodule. She is currently
being evaluated for further treatment considerations.
Mantle cell lymphoma (MCL) is associated with or discussed with the
indolent forms of NHL, although its behavior is more often that of an
aggressive lymphoma. Mantle cell lymphoma comprises about 6% of all adult NHLs
in the United States. The ratio of males to females affected is about 4:1.
About 70% of patients present with stage IV disease, with 40% of
patients having symptoms consisting of fevers, night sweats and weight loss.
Other symptoms include generalized lymphadenopathy, abdominal distention from
hepatosplenomegaly, fatigue from anemia or bulky disease. Less common symptoms
are caused by extranodal involvement of the gastrointestinal tract, lungs and
central nervous system.
splenomegaly with higher intensity of uptake relative to the liver, suggestive
of diffuse splenic involvement with lymphoma.
sagittal and coronar PET images and MIP image demonstrating diffuse marrow
activity suggestive of diffuse bone marrow involvement with lymphoma. There is
again marked splenomegaly with higher intensity of uptake relative to the
liver, suggestive of diffuse splenic involvement with lymphoma.
Tumor cells are monoclonal B cells that express surface immunoglobulin,
IgM or IgD. Cells are characteristically CD5+ and pan B-cell antigen positive
(eg, CD19, CD20, CD22) but lack expression of CD10 and CD23. Cyclin D1 is
overexpressed. Immunophenotyping helps differentiate MCL from other small
Genetic studies reveal immunoglobulin heavy and light chain genes
rearrangement. Overexpression of cyclin D1 in MCLs is strongly associated with
the t(11;14)(q13;q32), a translocation between the cyclin D1 (BCL-1,CCND1,
PRAD1) locus and the immunoglobulin heavy chain (IgH) locus. Only 50% to 65% of
MCLs will show the t(11;14) by cytogenetics, but by FISH, a much higher
fraction of cases with cyclin D1 overexpression contain the BCL-1/IgH fusion
Not all patients with MCL require immediate treatment. The decision to
treat is based on numerous variables, including lab studies, bone marrow
analysis, disease burden and/or imaging studies. Combination chemotherapy
remains the main treatment modality. The most frequently used conventional
chemotherapy regimens for MCL are standard or modified CHOP, CVP
(cyclophosphamide, vincristine, prednisone) and FC (fludarabine and
cyclophosphamide). The anti-CD20 monoclonal antibody rituximab, used as a
single agent, has activity in MCL, yielding a response rate of 35%, a complete
response rate of 10% to 15%, and a median duration of response of approximately
1 year in rituximab-naive patients.
In one study, PET and CT findings were investigated in 37 patients with
MCL (239 scans) and categorized following standardized response criteria for CT
evaluation (IWC-criteria), PET evaluation (EORTC-criteria) and combined PET/CT
evaluation (IWC + PET-criteria). FDG-PET showed a high sensitivity for the
detection of deposits of MCL and a higher FDG-uptake was shown in patients with
the more aggressive blastoid-variant MCL vs. common MCL. However, routine use
of PET for end-of-treatment response assessment in MCL cannot be recommended
because CT- and PET-based designation systems had equivalent prognostic value.
PET-based end-of-treatment response assessment only provided additional
information over CT-based response assessment in a subpopulation of patients
with highly FDG-avid MCL. PET allowed early detection of preclinical relapse
during post-therapy surveillance, but the therapeutic consequences of such
information are currently unclear.
Munir Ghesani, MD, is an attending radiologist at St.
Luke’s-Roosevelt Hospital Center, and Beth Israel Medical Center and a
HemOnc Today section editor. He is an associate clinical professor
of radiology at Columbia University College of Physicians and Surgeons.
Rami Daya, MD, is a practicing oncologist in Brooklyn, New York.
Amit A. Patel, MD, is a fellow in hematology/oncology at St.
For more information:
- Brepoels L. Leuk Lymphoma. 2008;49:1693-1701.
- Inghirami G. Blood. 1991;78:1503-1515.
- Martin P. J Clin Oncol. 2009;27:1209-1213.
- Non-Hodgkin’s Lymphoma Classification Project.
- Orchard J. Blood. 2003;101:4975-4981.
- Schulz H. J Natl Cancer Inst. 2007;99:706-714.
- Stein H. Adv Cancer Res. 1984;42:67-147.
- Weisenburger DD. Cancer. 1982;49:1429-1438.